For example, brigatinib (Alunbrig), a novel dual kinase inhibitor of ALK and EGFR, was approved by FDA in April 2017 and used for first-line treatment of locally advanced or metastatic ALK-positive NSCLC patients [87]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.